Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Lipids such as ceramides and phosphatidylcholines (PC) have been found altered in the plasma of Alzheimer's disease (AD) patients in a number of discovery studies. For this reason, the levels of 6 ceramides and 3 PCs, with different fatty acid length and saturation levels, were measured in the plasma from 412 participants (AD n = 205, Control n = 207) using mass spectrometry coupled with ultra-performance liquid chromatography. After this, associations with AD status, brain atrophy, and age-related effects were studied. In the plasma of AD participants, cross-sectional analysis revealed elevated levels of three ceramides (Cer16:0 p < 0.01, Cer18:0 p < 0.01, Cer24:1 p < 0.05). In addition, two PCs in AD plasma (PC36:5 p < 0.05, PC38:6 p < 0.05) were found to be depleted compared to the control group, with PC36:5 also associating with hippocampal atrophy (p < 0.01). Age-specific analysis further revealed that levels of Cer16:0, Cer18:0, and Cer20:0 were associated with hippocampal atrophy only in younger participants (age < 75, p < 0.05), while all 3 PCs did so in the older participants (age > 75, p < 0.05). PC36:5 was associated with AD status in the younger group (p < 0.01), while PC38:6 and 40:6 did so in the older group (p < 0.05). In this study, elevated ceramides and depleted PCs were found in the plasma from 205 AD volunteers. Our findings also suggest that dysregulation in PC and ceramide metabolism could be occurring in different stages of AD progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
MIND diet associated with reduced incidence of Alzheimer's disease
Morris, M. C., Tangney, C. C., Wang, Y., Sacks, F. M., Bennett, D. A., & Aggarwal, N. T. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.009 · Cited by 1,162 · cited 1×
“-3 PUFAs are well known for their neuroprotective properties in brain with higher omega-3 content being associated with lower incidence of dementia [32, 33].”
BackgroundComparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer Disease
Chan, R. B., Oliveira, T. G., Cortes, E. P., Honig, L. S., Duff, K. E., Small, S. A., Wenk, M. R., Shui, G., & Di Paolo, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274142 · Cited by 630 · cited 1×
“Detailed information regarding data acquisition, pre-processing, and quality control assessment have been described for this cohort elsewhere [16, 17].”
Han, X., Rozen, S., Boyle, S. H., Hellegers, C., Cheng, H., Burke, J. R., Welsh-Bohmer, K. A., Doraiswamy, P. M., & Kaddurah-Daouk, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021643 · Cited by 429 · cited 1×
“As mentioned previously, there are several studies that have reported ceramide elevation in AD brain [5, 8, 20] and others, which report increased expression of sphingomyelinase, the enzyme that synthesizes ceramides [21, 22].”
BackgroundHuman serum metabolic profiles are age dependent
Yu, Z., Zhai, G., Singmann, P., He, Y., Xu, T., Prehn, C., Römisch‐Margl, W., Lattka, E., Gieger, C., Soranzo, N., et al. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00865.x · Cited by 340
Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases
Filippov, V., Song, M. A., Zhang, K., Vinters, H. V., Tung, S., Kirsch, W. M., Yang, J., & Duerksen-Hughes, P. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111202 · Cited by 264 · cited 1×
“As mentioned previously, there are several studies that have reported ceramide elevation in AD brain [5, 8, 20] and others, which report increased expression of sphingomyelinase, the enzyme that synthesizes ceramides [21, 22].”
BackgroundMielke, M. M., Haughey, N. J., Bandaru, V. V. R., Schech, S., Carrick, R., Carlson, M. C., Mori, S., Miller, M. I., Ceritoglu, C., Brown, T., et al. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.014 · Cited by 170
Kester, M. I., Goos, J. D. C., Teunissen, C. E., Benedictus, M. R., Bouwman, F. H., Wattjes, M. P., Barkhof, F., Scheltens, P., & van der Flier, W. M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.754 · Cited by 161 · cited 1×
“AD participants were slightly older than controls; this is usual in AD studies with a relatively larger sample size [18, 19].”
ResultElevated stearoyl-CoA desaturase in brains of patients with Alzheimer’s disease
Astarita, G., Jung, K.-M., Vasilevko, V., DiPatrizio, N. V., Martin, S. K., Cribbs, D. H., Head, E., Cotman, C. W., & Piomelli, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024777 · Cited by 146 · cited 1×
“Detailed information regarding data acquisition, pre-processing, and quality control assessment have been described for this cohort elsewhere [16, 17].”
Cited by
Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies
Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353
Guide to Metabolomics Analysis: A Bioinformatics Workflow
Chen, Y., Li, E.-M., & Xu, L.-Y. (2022) · Metabolites · doi:10.3390/metabo12040357 · Cited by 351
Neuroprotective Actions of Dietary Choline
Blusztajn, J., Slack, B., & Mellott, T. (2017) · Nutrients · doi:10.3390/nu9080815 · Cited by 293
Application of Metabolomics in Alzheimer’s Disease
Wilkins, J. M., & Trushina, E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2017.00719 · Cited by 268
Diverse roles of ceramide in the progression and pathogenesis of Alzheimer's disease
Chowdhury, M. R., Jin, H. K., & Bae, J.-S. (2022) · Biomedicines · doi:10.3390/biomedicines10081956 · Cited by 47
Metadata
- Authors
- Kim, M., Nevado-Holgado, A., Whiley, L., Snowden, S. G., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Thambisetty, M., Dobson, R. J. B., Powell, J. F., Lupton, M. K., Simmons, A., Velayudhan, L., Lovestone, S., Proitsi, P., & Legido-Quigley, C.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2017-10-03
- Volume
- 60
- Issue
- 3
- Pages
- 809-817
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2557359439
- Cited by
- 96
- References
- 11
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.